Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
伊克力西斯(US:EXEL) Businesswire·2025-10-20 06:30临床试验结果 - 公司公布STELLAR-303全球三期关键试验的详细结果 该试验评估zanzalintinib联合atezolizumab对比regorafenib用于治疗既往经治的非微卫星不稳定性高转移性结直肠癌患者 [1] - 研究达到其双重主要终点之一 证明联合疗法可使死亡风险降低20% [1]